MCL1 and neoplasm: While others have previously established that venetoclax monotherapy induces MCL1 levels and confers resistance51, the combination of BRD-810 and venetoclax was synergistic and able to elicit complete response in all animals, with no tumor recurrence during the 4 weeks of post-treatment monitoring.